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It is now appreciated that different homologous immtmoglobulius are capable 
of preparing the rat peritoneal cavity  for the antigen-induced release of distinctly 
different chemical  mediators  of  anaphylaxis  (1).  One  antibody,  the  "mast 
cell-seusitlzlng"  (2)  or  homocytotropic  (3)  antibody,  appears  early  in  the 
course of immunization and sensitizes rat mast cells  in vivo  (4)  and  in  vi- 
tro (3, 5) for the release of histamine and serotonin upon subsequent interac- 
tion with specific antigen. A second homologous antibody associated with the 
IgG fraction of hyperimmune rat antisera (1) prepares the rat for the selective, 
antigen-induced release of slow reacting substance of anaphylaxis (SRS-A~*). 
In  a  series  of preliminary experiments  using heterologous,  hyperimmune 
antisera (6),  it appeared that, in the rat, the polymorphonuclear (PMN) leu- 
kocyte was  a  cellular prerequisite  for  the  immunologic release  of SRS-A  ~t, 
whereas the peritoneal mast cell and circulating lymphocyte were not required. 
The present study confirms and extends this observation using homologous, 
hyperimmune antisera. The immunologic release of SRS-A  ~t was suppressed 
by leukocyte depletion, and it was enhanced in the presence of an intraperi- 
toneal exudate consisting predominantly of PMN leukocytes. 
Inhibition of the antigen-induced release of SRS-A  ~t by diethylcarbamazine 
is also described. This piperazine analogue blocks the immunologic pathway 
leading to the release of SRS-A  ~t without interfering with the antigen-induced 
release of histamine. Thus, the reaction sequences initiated by interaction of 
specific antigen with distinctly different homologous immunoglobulins leading 
to the selective release of either SRS-A  ~t or histamine involve different cellular 
elements  and  can be  inhibited by different biological and  chemical  agents. 
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Materials and Methods 
Materials.--Male Sprague-Dawley rats weighing 20(0450 g were used in all experiments; 
rats of comparable sizes were used in each experiment. Albino rabbits weighing 2-4 kg were 
used in the preparation of antisera against various rat cell types. 
Bovine serum albumin (BSA) and hen egg alb.mln  (Ea) were supplied by Pentex Inc., 
Kankakee,  Ill.  Dinitrophenyl bovine 5'-globulin  (DNP-B3'G)  and  dinitrophenyl bovine 
serum albumin (DNP-BSA) were prepared as described (7); DNP-B3'G and DNP-BSA con- 
mined 34 and 31 haptenic groups/mole of protein, respectively. 
Nitrogen  mustard  (Mustargen)  was obtained from Merck,  Sharp  &  Dohme  (Rahway, 
N. J.). Diethylearbamazine citrate (Hetrazan, Lederle Laboratories, Pearl River, N. yr.) was 
generously  supplied  by  Dr.  H.  G.  Loekhard  (Lederle  Laboratories).  The  antihistamine, 
mepyramine maleate  (Neo-Antergan, Merck,  Sharp  & Dohme), and a  potent antlserotonin 
agent, methysergide (UML-491, Merck, Sharp & Dolmae), were used in the bioassays. 
A  semipurified, nontoxic fraction of venom from the cobra (Naja haje) (8)  was donated 
by Dr. R. A. Nelson. The Bacillus partussis cultures were supplied by Dr. Irving Millman of 
Merck,  Sharp  & Dohme. 
ImmunCzation Proctdmre~.--Hyper~mmune rat antisera were obtained by injecting 10 nag 
of BSA or Ea emulsified in 1.0 ml of complete Freund's adjuvant  (Difco Laboratories, De- 
troit, Mich.) into the foot-pads of male Sprague-Dawley rats. 7 days later, the animals were 
injected intramuscularly in the thigh and at three rites subcutaneously with a  total of 4-5 
nag of antigen in 1.0 ml of complete Freund's adjuvant. On days 28-30, the rats were injected 
intradermally at  two rites on a  shaved area of their backs with 0.1  ml of a  solution con- 
tsinlng 100/.tg of specific antigen in 0.15 ~  saline. The animals were exsanguinated 35-40 
days after initial immunization, and the sera stored at -- 70°C. 
Hyperimmune rat antiserum against DNP-B~/G was obtained by injecting male Sprague- 
Dawiey rats with an emnirion of 2.0 nag DNP-BTG in 1.0 ml of complete Freund's adjuvant; 
each rat received 0.1 ml in each foot-pad and 0.6 ml intraperitoneally. 7 days later, 1.0 nag 
of DNP-B'yG in complete Freund's adjuvant was injected intramuscularly in the thigh and 
subcutaneously at three sites on the back. On day 27, the rats were injected intradermally 
at two rites with 0.1 ml of a solution containing 100 #g DNP-B'yG in 0.15 ~  saline. This was 
repeated 1 wk later. The serum was obtained between days 35 and 45. 
Antisera containing homocytotropic antibody were prepared as described in reference 2. 
Rats were injected intramuscularly with 1.0 nag Ea in  1.0 ml 0.15 ~  saline and intraperi- 
toneally with 1.0 ml of a heat-killed B. pertussis culture containing 2  X  109  organisms/ml. 
Antlsera were obtained 10-14 days later. 
Rabbit antisera directed against rat mast cells were prepared as described in reference 9. 
Rabbit antisera directed against rat-thymic lymphocytes were  generously  supplied by  Dr. 
C.  B.  Carpenter  (10).  Rabbit anti-rat PMN leukocyte antiserum was kindly supplied  by 
Dr.  C.  G.  Cochrane or was prepared  as follows:  10 male Sprague-Dawley  rats were  each 
injected intraperitoneally with 20 mi of distilled water. 5 days later, they were injected intra- 
peritoneaUy with 20 ml of 0.1%  oyster glycogen  (Baker Chemical Co., North Phillipsburg, 
N. J.) in 0.15 ~t saline, and 4 hr later, the peritoneal cells were recovered in 10 ml Tyrode's 
solution containing heparin, 50 #g/ml. The cells were washed three times in Tyrode's solu- 
tion, pooled, and resuspended in 10 ml of buffer. The cell suspension containing about 1 X 
l0  s cells/mi (> 70% PMN leukocytes) was emulsified in 10 ml of complete Freund's adjuvant. 
5.0 ml of this emulsion were injected into the toe-pads and foot-pads of albino rabbits; and 
7 days later, an additional 5.0 ml were injected intramuscularly in the thigh and at  three 
sites subcutaneously. On day 28,  the rabbits were exsanguinated and  the serum obtained 
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Measurement of Antibody and Complement.--The  specific  antibody protein concentration 
of hyperimmune rat antisera was determined by precipitin analysis  (11). Hyperimmune rat 
antisera against BSA or Ea contained 2.0-5.8 mg of specific antibody protein per milliliter. 
Rat  antiserum  against  DNP-B'yG contained  1.3  mg/ml of  hapten-specific  antibody  pro- 
tein (7). 
Passive cutaneous anaphylaxis (1, 12) was carried out to determine the titer of homocyto- 
tropic antibody  activity. 0.1  ml aliquots  of serial dilutions of  homologous  antisera  were 
injected intradermally into the shaved backs of male Sprague-Dawley rats weighing 225-250 
g; 48 hr later, the animals were injected intravenously  with  1.0 mg  of  specific  antigen  in 
1.0 ml of 0.5% Evan's blue dye  (Allied  Chemical Co.,  Morristown, N.  J.).  45  rain  later, 
the animals were sacrificed  in ether,  the skin reflected, transilluminated,  and  the size and 
intensity of the lesions  were recorded. The serum pool used in experiments described below 
had  a  tite:  of 1:30 0)- 
Whole serum complement determinations were carried out as described in reference 13. 
Preparation o]  Rats  for  the ImmUnologic Rdease of SRS-Arat.--Male  Spragne-Dawley 
rats were rejected intraperitoneally with hyperimmune rat  antiserum  diluted with 0.15 ~r 
saline so as to contain 1.0 mg of specific antibody protein. The pools of hyperimmune rat 
antisera used ranged in titer from 1.3-5.8 mg of specific antibody protein per milliliter. 2 hr 
later,  the rats were challenged intraperitoneally with 2.0 nag of specific  antigen in  5.0 ml 
Tyrode's  solution  containing  heparin,  50  /zg/ml.  Exactly  5  rain  later,  the  animals 
were stunned,  exsangninated,  and  the abdominal wall was incised and  reflected. The peri- 
toneal fluid was recovered with siliconized Pasteur  pipettes and  centrifuged at  150 g  for 
4 rain at 4°C; the supematants were collected in iced polypropylene tubes. The cell button 
was resuspended in 3.0 ml of Tyrode's solution and boiled for 8 min to extract the residual 
cellular histamine. Histamine and  SRS-A  rat were assayed on the isolated guinea pig ileum 
as described  (1). Representative samples were assayed on the estrous rat uterus (14) for the 
presence of bradykinin  and  serotonin. Using the experimental model described for the im- 
munologic release of SRS-A  rat, insignificant concentrations of bradykinin and serotonin were 
found. 
In one series of experiments, rats were injected intraperltonealiy with 20 ml of 0.1% oyster 
glycogen in 0.15 M saline 16-18  hr before being prepared for the antigen-induced release of 
of  SRS-A  rat  as  described  above.  In  the peritoneal  exudate  induced  with glycogen,  over 
70% of the cells were PMN leukocytes, and the remainder were mononuclear cells (15). 
In  certain  experiments, rats prepared  for the immunologic release of  SRS-A  rat by  the 
intraperitoneal injection of hyperimmune rat  antisera were challenged intravenously with 
specific  antigen 2 hr later. 5.0 ml of Tyrode's solution containing heparin, 50 ~g/ml, were 
injected  intraperitoneally  immediately after intravenous  challenge with  antigen,  and  the 
peritoneal fluid was recovered exactly 5 min later and treated as described. 
Other experiments involved rats actively sensitized against BSA as previously described. 
10-14 days after the last intradermal booster injections, these actively sensitized rats were 
challenged with 5.0  mg of specific  antigen in 5.0 ml Tyrode's solution containing heparin, 
50 #g/ml, administered intraperitoneally. Exactly 5 rain later,  the peritoneal fluid was re- 
covered and treated in the usual fashion. 
Preparation of Rats for the Antigen-Induced Rdease of Histamine.--Male  Sprague-Dawley 
rats weighing 200-250  g were injected intraperitoneally with 5.0 ml Tyrode's solution con- 
taining a  1:10 dilution of rat antisera with homocytotropic antibody activity against  Ea. 
4 hr later, the animals were challenged with 2.0 nag Ea in 5.0 ml Tyrode's solution containing 
heparin, 50/~g/ml. Exactly 5 min later, the peritoneal fluid  was  recovered and  treated  as 
above. Homocytotropic antibody-mediated histamine release was associated with serotonin 
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I~$ULTS 
Determination of the Cellular  Prerequisites  for the Antigen-Induced Rdease of 
SRS-A'*t.-- 
Effect  of depletion  of peritoneal  mast cells on  the subsequent  antigen-induced 
release  of SRS-A'*t:  Preliminary  experiments confirmed  the observation (16) 
that the intraperitoneal injection of distilled water into rats produced disrup- 
tion of the mesenteric mast ceils as determined by microscopic examination of 
spreads of mesentery stained with toluidine blue. Morphologic examination and 
estimations of the  total residual cellular histamine of the free peritoneal cells 
TABLE I 
The Antigen-Induced Rdease of SRS-A  rat in Rats Pretreated with Distilled Water or a Rabbit 
Modifying procedure 
A.  Control 
Distilled water 
Anti-Rat Mast Cell Antiserum (Ra Anti-RMC 
B.  Control 
Ra anti-RMC 
No. of 
rats 
Peripheral blood 
Total 
WBC* 
per mm  s 
9,275 
8,060 
8,450 
10,100 
Differential 
Poly  Lymph  Mono 
i 
27.3  70.0  2.7 
26.6  72.0  1.4 
24.0  72.5  3.5 
21.2  74.2  4.6 
Peritoneal 
cells 
Total 
cellular 
histamine 
ug/rat 
10.0 
0.05 
6.6 
0.08 
MeALn 
SRS-Arat 
release 
units~rat 
464 
488 
578 
512 
* WBC, white blood cells. 
Each result represents a mean value for the rats in that group. Rats were prepared with 
hyperimmune antiserum  against  DNP-B3'G for the release of SRS-A  rat,  and  they were 
challenged intraperitoneally with DNP-BSA. Distilled water (20 ml intraperitoneally) was 
injected 5 days before Experiment A, and Ra anti-RMC  (2.0 ml intraperitoneally) was in- 
jected 24 hr before Experiment B. 
established that the free peritoneal mast cells were also depleted by this pro- 
cedure (6). Rats pretreated with distilled water 5 days before being prepared 
for  the  antigen-induced  release  of SRS-A  rat  with homologous,  hyperimmune 
antiserum demonstrated no reduction in the release of SRS-A  mt when compared 
with untreated animals (Table I). The elimination of the peritoneal mast cell 
population by a  specific rabbit anti-rat mast cell  antiserum  (9)  also  did  not 
influence the subsequent immunologic release of SRS-A  ~t  (Table I), but did 
prevent  the  homocytotropic antibody-mediated  release  of histamine  (Table 
II). 
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rdease  of SRS-A'*t: Rats pretreated with nitrogen mustard, 2.0 mg/kg intra- 
venously, 5 days before an experiment developed a profound leukopenia, but 
the peritoneal mast cell population remained intact. When rats made leukopenic 
TABLE II 
The Antigen-Induced  Release  of Histamine in Rats Pretreated  with a  Rabbit  Anti-Rat Mast 
Cell Antiserum (Ra Anti-RMC) 
Modifying procedure 
Control 
Ra anfi-RMC 
No. of 
rats 
3 
3 
Peripheral blood 
Total WBC 
per mm  ~ 
10,100 
16,100 
Differential 
Peritoneal 
cells 
Total 
cellular 
Poly  ]  Lymph  Mono  histamine 
I  1 
IzglraJ 
22  77  1  17.4 
25  72  3  0.45 
Mean 
histamine 
release 
ug/rat 
8.2 
0.14 
Each result represents a mean value for the rats in that group. Rats were prepared with 
antiserum  containing homocytotropic antibody against  Ea and  were challenged intrapefi- 
toneaUy with Ea. Ra anti-RMC  (2.0 ml intraperitoneally) was injected 24 hr before experi- 
ment. 
TABLE III 
The Antigen-Induced  Release of SRS-A ~at in Rats Pretreated with Nitrogen  Mustard or Rabbit 
Anti-Rat Polymorphonuclear  Leukocyte Antiserum  Ra Anti-RPMN) 
Modifying procedure 
A.  Control 
Nitrogen mus- 
tard 
No. of 
ra ts 
B.  Control 
Ra anti-RPM]~ 
Total 
WBC 
per ram* 
11,666 
2,200 
15,683 
4,800 
Peripheral blood 
Differential 
Poly  Lymph  Mono 
24.7  73.0  2.3 
23.7  73.3  3.0 
24.3  73.1  2.6 
0.7  91.2  8.1 
Peritoneal 
cells 
Total 
cellular 
histamine 
t~g/rat 
15.3 
14.7 
11.4 
0.013 
--  Mean SRS- 
Arat 
release 
units~vat 
594 
146 
704 
129 
Suppres- 
sion 
% 
75.5 
81.8 
Each result represents a  mean value for the rats in that group. Rats were prepared with 
hyperimmune antiserum against Ea for the release of SRS-A  rat, and they were challenged 
intraperitoneally with Ea. Nitrogen mustard  (2.0 mg/kg intravenously) was injected 5 days 
before Experiment A, and  Ra  anti-RPMN  (3.0  ml intraperitoneally)  was injected  18  hr 
before Experiment B. 
with  nitrogen mustard  were then prepared  for  the  antigen-induced  release  of 
SRS-A  ~t  with  homologous  hyperimmune  antiserum,  a  76%  suppression  of 
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A  marked neutropenia was  effected in rats by the intraperitoneal injection 
of a rabbit anti- rat polymorphonuclear leukocyte antiserum (Ra anti-RPMN). 
Rats  made  neutropenic  with  this  antiserum  demonstrated  more  than  80% 
suppression of the antigen-induced release of SRS-A  rat (Table III). In contrast 
TABLE IV 
The Antigen-Induced  Release of SRS-A rat in Rats Pretreated with a Rabbit  Anti-Rat  Thymic 
Lymphocyte Antiserum  (Ra Anti-RTL) 
Modifying procedure 
Control 
Raanti-RTL 
Peripheral blood 
Total 
WBC 
per mm  s 
16,400 
5,340 
Differential 
Peritoneal 
cells 
Poly  ____Lymph  Mono 
,ug/rat 
23.8  74.6  1.6  19.6 
61.2  I  34.6  ]  4.2  ]  12.8 
Total 
cellular 
histamine 
Mean SRS- 
A  rat release 
undCs/rat 
524 
735 
Each result represents a mean value for the rats in that group. Rats were prepared with 
hyperimmune antiserum against Ea for the release of SRS-A  rat, and they were challenged 
intraperitoneally with Ea.  Ra anti-RTL  (0.3 ml intravenously) was injected 4  hr before 
experiment. 
TABLE V 
The Antigen-Induced  Rdease of SRS-A rat  in the Rat Peritoneal  Cavity  in the Presence  of a 
Polymorphonuclear  Leukocyte  (PMN) Exudate 
Modifying procedure 
Control 
PMNexudate 
Control 
PMNexudate 
No. of rats 
Peritoneal fluid 
Total ceils per mm~ 
17.8 X  103 
50.7 X  103 
22.4 X  103 
62.3 X  108 
PMN 
% 
5.0 
75.0 
6.0 
89.0 
Mean SRS- 
A  rat release 
units~rat 
200 
450 
282 
1033 
Each result represents a mean value for the rats in that group. Rats were prepared with 
hyperimmune antiserum against BSA for the release of SRS-A rat, and they were challenged 
intraperitoneally  with BSA. The PMN exudate was induced by the intraperitoneal injection 
of 0.1% oyster glycogen 18 hr before each experiment. 
to the nitrogen mustard, the Ra anti-RPMN also depletes the rats of peritoneal 
mast  cells, but previous experiments (Table I)  had  ruled out  any significant 
role for the peritoneal mast cell in this reaction. 
The leukopenia induced by nitrogen mustard involved lymphocytes as well 
as PMN  leukocytes, whereas pretreatment  with Ra  anti-RPMN  produced a R.  P.  ORANG~E~ M.  D.  VALENTINE~ AND  K.  ~'.  AUSTEN  773 
marked neutropenia with only a moderate reduction in the absolute lymphocyte 
counts. The possible role of the lymphocyte was further studied by experiments 
involving pretreatment of  rats  with  a  rabbit antiserum directed against rat 
TABLE VI 
The Antigen-Induced  Release of S~-A  rat in the Peritoneal Cavity of Actively Sensitized  Rats 
in the Presence of a Polymorphonuclear Leukocyte (PMN) E~udate 
Modifying procedure 
Control 
PMN exudate 
No. of rats  Mean  weight 
g 
435 
452 
Mean SRS-A  rat release 
unlts/rat 
377 
2174 
Each result represents a mean value for the rats in that group. Rats actively sensitized 
against BSA were challenged intraperitoneally  with BSA. The PMN exudate was induced 
by the intraperitoneal injection of 0.1% oyster glycogen 16 hr before the experiment. 
TABLE VII 
Changes in Whole Serum Complement (CIt6o) in the Rat Produced by 
Different Modifying  Procedures 
Modifying procedures 
Antigen challenge 
Rabbit anti-rat mast cell antiserum 2.0 ml intraperitoneally 24 
hr before testing 
Rabbit anti-rat polymorphonuclear leukocyte antiserum 3.0 ml 
intraperitoneally  24 hr before testing 
DistiUed water 20 ml intraperitoneally  5 days before testing 
Nitrogen mustard 2.0 mg/kg intravenously  5 days before test- 
ing 
Rabbit anti-rat thymic lymphocyte  antiserum  0.3 ml intra- 
venously 4 hr before testing 
Nontoxic fraction of cobra venom (Naja haje) 0.5 ml and 0.25 
ml intravenously 24 and 4  hr respectively before testing 
Mean whole serum 
complement (CHs0) 
Control  E ~peri-  n .ental 
170  120 
234  203 
234  161 
209  289 
2O9  274 
197  179 
172  0 
Reduction 
l 
% 
29.4 
13.3 
31.2 
m 
9.2 
100 
Each result represents a mean value for six rats in each group. Experimental  group of 
rats challenged with antigen were prepared for SRS-A  rat release by the intraperitoneal  in- 
jection of hyperimmune antiserum against Ea. Control animals in this group received only 
antigen intraperitoneally.  All other control groups represent normal rats of similar weight 
to experimental animals tested that day. 
thymic lymphocytes (Ra  anti-RTL). This antiserum effected a  greater than 
80 % reduction in the absolute lymphocyte count without significant change in 
the  circulating PMN  leukocyte population or  suppression of  the  subsequent 
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Effect of an intraperitoneal PMN leukocyte  exudate on the subsequent antigen- 
induced release of SRS-Ara*: A  peritoneal  exudate consisting predominantly of 
PMN leukocytes and representing a 40- to 50-fold absolute increase in this cell 
type was induced in rats by the intraperitoneal injection of glycogen 18 hr before 
preparation for the antigen-induced release of SRS-A  rat. As shown in Table V, 
the  antigen-induced  release  of SRS-A  ~at was  enhanced  twofold to fourfold in 
the  presence  of  a  peritoneal  exudate.  No  attempt  was  made  to  determine 
200 I- 
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FIG. 1. Sequential changes in CHb0 and SRS-A  rat release in rats pretreated  with cobra 
venom fraction. Each point represents a mean value for three rats in that group. Rats were 
prepared with hyperimmune antiserum against Ea, and they were challenged intraperitoneaUy 
with Ea. Cobra venom factor (0.5 ml and 0.25 ml) was injected intravenously  24 and 4 hr 
respectively before the start of the experiment. Values were expressed as per cent of normal 
value for comparable group of untreated  rats each day. 
whether the use of greater concentrations of antiserum and antigen would lead 
to an even greater enhancement of SRS-A  ~t release in the presence  of a  peri- 
toneal exudate.  When a  peritoneal  exudate was induced in actively sensitized 
rats prior to intraperitoneal challenge with specific antigen, a sevenfold enhance- 
ment in the release of SRS-A  r=* was observed (Table VI). 
E Bect of pretreatment with a nontoxic fraction of cobra ~enom on the subsequent 
antigen-induced release of SRS-A'~*: The immunologic release of SRS-A  '=t, using 
homologous  hyperimmune  antiserum  to  prepare  the  peritoneal  cavity,  was 
associated  with  a  slight  reduction  in  whole serum  complement  (Table  VII). R. P. ORANGE,  M.  D. VALENTINE,  AND  K. F. AUSTEN  775 
Thus, attention was directed to the effect of decomplementation by pretreat- 
ment with a semipurified, nontoxic fraction of cobra venom (Naja haje) on the 
subsequent release of SRS-A  ~t. Fig. 1 depicts the results of an experiment con- 
cerned with  the sequential changes in the  CH60 and the release of SRS-A  ~t 
in rats pretreated with this cobra venom fraction as compared with normal rats. 
Both parameters were markedly reduced during the first 3 days and gradually 
returned to normal within the next 3  days with SRS-A~t-releasing capacity 
being fully restored to normal somewhat earlier than whole complement activ- 
ity. 
Since  complement  depletion  suppressed  the  antigen-induced  release  of 
SRS-A'**, the effect of the various modifying procedures on the CHso of the rat 
TABLE VIII 
Inhibition  of the Antigen-Induced  Rdease of SRS-A rat with Intraperitoneal Dietkylaarbamazine 
Diethylcarbamazine (mg/kg)  mtraperitoneally  Mean SRS-Arat release  Inhibition 
0 
5 
10 
20 
40 
unlts/rat 
235 
272 
162 
92 
67 
% 
32 
61 
72 
Each result represents a mean value for the rats in that group. Rats were prepared with 
hyperlmmtme antiserum against BSA for the release of SRS-A  rat, and they were challenged 
intraperitoneally with BSA. Diethylcarbamazine  was injected intrapedtoneally 30 sec before 
challenge with specific  antigen. 
was determined (Table VII). None of the modifying procedures significantly 
diminished the titer of whole complement in the rat except pretreatment with 
the cobra venom fraction. 
Effect  of Diethylcarbamazine  on  the  Antigen-Induced  Release  of SRS-Ar% - 
The observation that  diethylcarbamazine  (Hetrazan)  suppressed  the  anti- 
gen-induced  release  of  SRS-A  "t  in  rats  prepared  with  heterologous hyper- 
immune  antiserum  without  interfering  with  the  bioassay  of  SRS-A  ~t  (17) 
prompted an assessment of its action in rats prepared with homologous, hyper- 
immune  antiserum.  When  diethylcarbamazine  was  administered  intraperi- 
toneally 30 sec before challenge with specific antigen by the same route, a dose 
of  20  mg/kg  consistently gave  greater  than  60%  suppression  of  SRS-A  ~t 
release (Table VIII). 
Since it had already been established that diethylcarbamazine did not inter- 
fere with antigen-antibody interaction in vitro (17), an experiment was devised 776  ANTIGEN-INDUCED  RELEASE  OF  SRS-A  IN  RATS 
to show that  diethylcarbamazine would  not interfere  with  antigen-antibody 
interaction in vivo. If antigen-antibody interaction does indeed occur in vivo 
in the antigen-challenged, diethylcarbamazine-treated rat,  then such an animal 
should be unresponsive  to a  second challenge with  specific antigen at  a  time 
when diethylcarbamazine has  been excreted to  a  noninhibitory  level  (Table 
IX).  When  animals  prepared  with  homologous hyperimmune  antiserum 
were  challenged with antigen at  1  hr  without  being sacrificed  and  then  re- 
challenged at  2 hr,  the  peritoneal  fluid  contained  very little  SRS-A  ~t  be- 
cause the  initial  antigen  challenge  utilized  most  of  the  available  antibody, 
and the SRS-M  at  released had been  inactivated  in  vivo.  When animals  sen- 
sitized in the same manner were challenged with  antigen at  1 hr in the pres- 
TABLE IX 
"Desensitization"  of Rats Prepared for the Antigen-Induced  Release of SRS-A ra¢ 
~th Homologous Antibody by Pretreatment with Specific Antigen in the 
Presence and Absence of Diethylcarbamazine 
Modifying procedures  No. of rats  SRS-Arat  Suppression  release 
Antigen alone at 2 hr 
Antigen +  diethylcarbamazine at 2 hr 
Antigen alone at 1 hr +  repeat antigen dose at 2 
hr 
Antigen +  diethylcarbamazine at  1 hr  +  re- 
peat antigen dose alone at 2 hr 
units~rat 
380 
105 
50 
41 
% 
72.4 
87.0 
89.3 
Each result represents a mean value for the rats in that group. Rats were prepared with 
hyperimmune antiserum against BSA for the release of SRS-A  rat, and they were challenged 
intravenously with BSA. Diethylcarbamazine (20  mg/kg intravenously) was injected 30 
sec before challenge with specific antigen. 
ence of diethylcarbamazine and  then were  rechallenged at  2 hr with  antigen 
alone, there again was no appreciable release of SRS-A  ra*. In the latter  group, 
the failure of the  repeat  challenge  to  release  SRS-A  rat  cannot  be  attributed 
to the presence of diethylcarbamazine because this drug is excreted  at  a rate 
of  100  mg/kg/hr  (18),  and a  20 mg/kg dose is no longer inhibitory  15 rain 
after administration (17).  This dose of diethylcarbamazine effected a  72 % in- 
hibition  of the  immunologic release  of  SRS-M  a*  when  administered  at  the 
time  of challenge  with  specific  antigen  (Table  IX).  Thus,  inhibition  of  the 
antigen-induced release of SRS-A  ra* by diethylcarbamazine is associated with 
"desensitization"  of  the  tissues  since  effective  antigen-antibody  interaction 
takes place but the reaction sequence initiated by this interaction is blocked by 
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Inhibition  of SRS-A "a* Release in the Actively Sensitized Rat.-- 
Inhibition of the antigen-induced release of SRS-A  rat was also achieved in 
actively sensitized rats by depletion of the circulating PMN leukocytes; greater 
than 95 % suppression of the antigen-induced release of SRS-A  ~t was observed 
when the absolute PMN leukocyte count was reduced by pretreatment with Ra 
anti-RPMN to less than 2 % that of control animals (Table X). Diethylcarbam- 
azine in a dose of 20 mg/kg intraperitoneally given  at the time of challenge 
with  specific  antigen  also  markedly suppressed  the immunologic  release of 
SRS-A  ra* in the actively sensitized rat (Table X). 
TABLE  X 
Inhibition of the Antigen-Induced Release of SRS-A Tat in Activd,, Sensitized Rats 
Modifying  procedure 
Control 
Ra anti-RPMN 
Diethylcarbamazine 
No. of 
rats 
Peripheral blood 
Total  [  Differential 
WBC 
.....  per mm~  Poly  Lymph  Mono 
 8,40°127  I  70  t  3 
7,300  I  1  I  9415 
20,400128  t  70  I  2 
eritone~ 
cells 
Total 
cellulal 
Listamir 
#g/rat 
9.2 
0.40 
13.8 
Mean SRS- 
A  rat  release 
1488  ] 
Suppres- 
sion 
% 
95.4 
87.6 
Each result represents a mean value for the rats in that group. Rats were hyperimmunized 
against BSA  and  challenged intraperitoneally with BSA for the release of  SRS-A  rat.  Ra 
anti-RPMN  (3.0 ml intraperitoneally) was injected  16 hr before the experiment, and di- 
ethylcarbamazine  (20 mg/kg intraperitoneally) was injected 30 see before challenge with 
specific antigen. 
DISCUSSION 
Requirement for the PMN Leukocyte in the Reaction Sequence Leading to the 
Antigen-Indueed  Release of SRS-A~t.--The implication of the mast cell in the 
daboration of slow reacting substance of anaphylaxis is based upon the findings 
that, in guinea pig lung slices, the quantity of SRS-A  *p released appears pro- 
portional to the release  of histamine (19) and that  homologous  ~l-immuno- 
globulins prepare the tissue for the subsequent antigen-induced release of both 
mediators (1). A slow reacting substance has also been released in small quanti- 
ties from isolated peritoneal  mast cells (20). However, the ratio of histamine 
(m/~g) to SRS (units) released from guinea pig lung was 5:1, whereas the ratio 
for isolated rat peritoneal mast cells was 240:1, suggesting that in the rat the 
mast cell may not be a major source of SRS-A (21). In the rat, the homocyto- 
tropic antibody-mediated release of histamine is not associated  with the con- 
comitant appearance of SRS-A  ~t (1). The present experiments further corrobo- 
rate the thesis that the mast cell is not a prerequisite  for the antigen-induced 778  ANTIGEN-INDUCED  RELEASE  OF  SRS-A  IN  RATS 
release of SRS-A  ~t since depletion of free and tissue peritoneal mast cells by 
pretreatment with distilled water or a  rabbit anti-rat mast cell antiserum had 
no effect on the subsequent immunologic release of SRS-M  a* in rats prepared 
with  homologous  hyperimmune  antiserum  (Table  I).  However,  mast  cell 
depletion  did prevent the antigen-induced release of histamine following sen- 
sitization  with  antiserum  containing  homocytotropic  antibody  (Table  II). 
The role of the PMN leukocyte in the immunologic pathway leading to the 
formation and release of SRS-A  rat was initially investigated by studying  the 
effects of leukocyte depletion.  When  leukopenia was induced  in  rats by pre- 
TABLE XI 
The Effect of Pretreatment with Nitrogen Mustard on the Antigen-Induced Rdease of Histamine 
ancl SRS-A mt in the Rat Peritoneal Cavity 
Modifying procedure 
Control 
Nitrogen mustard 
Sensitization with hyperimmune 
rat antisera 
SRS-Ara  t  release 
units~rat 
326 
126 
Sensitization  with rat antiserum 
containing homocytotropic 
antibody 
Histamine release 
ug/rat 
2.2 
4.4 
Each result represents a mean value for the three rats in that group. Rats were prepared 
with hyperimmune antiserum against BSA for the release of SRS-A  rat, and they were chal- 
lenged intraperitoneaIly with BSA. Rats were prepared with rat antiserum containing homo- 
cytotropic antibody against Ea for the release of histamine, and they were challenged in- 
traperitoneally with Ea. Nitrogen mustard  (2.0 mg/kg intravenously) was injected 5 days 
before experiment. The mean peripheral WBC for control group releasing SRS-A  rat was 
16,010/mm  3 and for control group releasing histamine, 15,970/mm  ~, whereas the values for 
the nitrogen mustard-treated  groups were 1020/ram  ~ and  1070/ram  8 respectively. 
treatment  with  nitrogen  mustard  (Table III), a  marked  suppression  of  the 
antigen-induced release of SRS-A  ra* was observed. Although nitrogen mustard 
did not alter the peritoneal mast cells as assessed by morphologic examination 
and quantitative histamine analysis of the residual peritoneal cell population, 
it was important to establish the functional integrity of this cell population by 
their ability to participate in an immunologic reaction sequence. As described 
in  Table XI,  leukopenic  rats  retaining  their  peritoneal  mast  cells  could  be 
prepared for the antigen-induced  release  of histamine following sensitization 
with antiserum containing homocytotropic antibody, whereas the immunologic 
release  of SRS-A  ~at following preparation  with  hyperimmune antiserum  was 
markedly suppressed. Thus, inhibition of SRS-A  ~* release by nitrogen mustard 
can be attributed to the induced leukopenia and not to some nonspecific tissue 
unresponsiveness. 
The depletion  of lettkocytes following pretreatment with nitrogen mustard 
involved lymphocytes as well as PMN leukocytes; thus, attempts were made to 
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logic release of SRS-A  '*t. Pretreatment of rats with a rabbit antisermn directed 
against rat thymic lymphocytes effected a greater than 80 % reduction in the 
absolute  lymphocyte count without significantly altering the population of 
PMN leukocytes, and no suppression of the antigen-induced release of SRS-M  a* 
was observed (Table IV). Conversely, pretreatment of rats with a rabbit anti- 
serum directed against rat PMN leukocytes produced a profound neutropenla, 
moderate lymphopenla, and marked suppression of the antigen-induced release 
of SRS-A  ~"t (Table III). Rats depleted of circulating PMN leukocytes by pre- 
treatment with a rabbit anti-rat PMN leukocyte antiserum were injected intra- 
venously with 5.0 ml of pooled, washed, peritoneal exudate cells (> 70 % PMN 
leukocytes)  in an attempt to reconstitute their population of circulating leuko- 
cytes. Although only 25 % restoration of the absolute peripheral  PMN leu- 
kocyte count was achieved,  this was  associated  with approximately a  20 % 
restoration of the ability to prepare  the rat with homologous, hyperimmune 
antiserum for the antigen-induced release of SRS-A  rat. Since further attempts to 
achieve complete repletion  of the circulatng PMN leukocytes were unsuccess- 
ful, attention was directed towards demonstrating enhancement of SRS-A  r~t 
release by a local increase in the number of PMN leukocytes. When the number of 
PMN leukocytes in the rat peritonal cavity was substantially increased by the 
induction of a peritoneal exudate in actively or passively sensitized  animals a 
twofold to  sevenfold  increase  in  the  subsequent  antigen-induced release  of 
SRS-A  r~* was observed (Tables V and VI). Thus, the PMN leukocyte is impli- 
cated in the immunologic  release  of SRS-A  ~*  on the basis  of inhibition of 
SRS-A  '*t release by specific depletion of this cell type, partial restoration of 
SRS-A  ~"t release associated  with partial repletion  of the circulating PMN leu- 
kocytes, and enhanced SRS-A  "~t release in the presence of an increased number 
of PMN leukocytes in the rat peritoneal cavity. 
In preliminary experiments,  the peritoneal exudates of actively sensitized 
rats were passively  transferred to the peritoneal cavities  of unsensitized  rats, 
and, upon subsequent challenge  with specific antigen, SRS-A  =t release  was 
achieved. The activity of the donor exudate could not be easily attributed to 
passive  sensitization  by free antibody since  the supematant fluid following 
sedimentation of the cells did not prepare  normal rats for SRS-A  '~* release, 
and the interval of 5 rain between transfer and antigen challenge was too brief 
a latent period to prepare the tissue for the immunologic release of SRS-A  ~'t 
(1).  These  observations  are  consistent with the essential  role  of the PMN 
leukocyte in the reaction sequence leading to the antigen-induced release  of 
SRS-A  =*. 
The precise role of complement in the immunologic release of SRS-A  r"t has 
not been established. The complement system may be required for the genera- 
tion of a leukotactic factor (22) or possibly enhancement of immune phago- 
cytosis (23).  A  non-complement-dependent mechanism of inhibition has not 
been  excluded, since crude cobra  venom has been observed  to release a slow 780  ANTIGEN-INDUCED  RELEASE  O1  ~  SRS-A  IN  RATS 
reacting material from perfused guinea pig lung (24) and thus could inhibit by 
depleting the substrate required  for the formation and release  of SRS-A  ~t. 
Separation  of the Reaction  Sequences Leading to the Antigen-Induced  Release 
SRS-A ~t and ttistamine.--The immunologic pathways to the antigen-induced 
release of histamine and SRS-A  r~t in the rat peritoneal cavity can be separated 
in  terms  of the homologus  immunoglobulins  which  prepare  the tissues,  the 
prerequisite  cellular  elements,  and by pharmacologic  inhibition studies.  The 
immunoglobulin  which  prepares  the  rat  for  the  antigen-induced  release  of 
SRS-A  r~ is associated with the IgG class, while the homocytotropic antibody 
which  sensitizes rat mast cells in vivo and in vitro for the antigen-induced 
release of histamine and serotonin represents  an immunoglobulin class distinct 
from IgG, IgA, or IgM (1, 25). The elimination of the free and tissue peritoneal 
mast cells prevents the antigen-induced release of histamine following sensitiza- 
tion with antiserum containing the homocytotropic antibody of the rat (Table 
II) but in no way suppresses the antigen-induced release of SRS-A  rat (Table I). 
In contrast, the elimination  of the circulating  PMN leukocyte prevents the 
antigen-induced  release of SRS-A  *a* following preparation with hyperimmune 
rat antiserum (Table III) but has no effect on the antigen-induced  release of 
histamine following sensitization  with antiserum containing homocytotropic 
antibody (Table XI). 
Finally, diethylcarbamazine administered intravenously or intraperitoneally 
suppresses the antigen-induced  release of SRS-A  r~t following preparation with 
hyperimmune antiserum but has no effect on the antigen-induced release of 
histamine after sensitization  with antiserum containing the homocytotropic 
antibody. As expected, this agent has no effect on the lesion of passive cutaneous 
anaphylaxis mediated by homocytotropic antibody which is fully suppressed 
by  a  combination of histamine and  serotonin  antagonists  (2).  Preliminary 
studies  indicate that only a combination of diethylcarbamazine, mepyramine, 
and  methysergide  will  abolish  the  lesion of passive  cutaneous anaphylaxis 
mediated by homologous hyperimmune antiserum (17);  the requirement for 
such a combination indicates the complexity of this lesion and the precise con- 
tribution by the pathway to SRS-A  ~* release remains  to be determined. It is 
apparent from the studies concerned with the antigen-induced,  intraperitoneal 
release of SRS-A  ~t that diethylcarbamazine  blocks at some point subsequent to 
antigen-antibody interaction and prior to the elaboration of  SRS-A  ~*  (17). 
Thus, inhibition of the antigen-induced  release of SRS-A  ~t by diethylcarbam- 
azine is  associated  with tissue  "desensitization"  because  the antigen  utilizes 
the available antibody in initiating a reaction that is then blocked at some sub- 
sequent step in the reaction sequence (Table IX). 
S~MMARY 
The polymorphonuclear leukocyte appears to be an essential  cellular  pre- 
requisite  for the antigen-induced release  of SRS-A  ~at  in the peritoneal  cavity of R.  P.  ORANGE,  l~r. D.  VALENTINE,  AND  K.  ~.  AUSTEiW  781 
rats  prepared  with  homologous,  hyperimmune  antisera.  Depletion  of PMN 
leukocytes is associated with a marked suppression of SRS-A  '~* release, whereas 
depletion of circulating lymphocytes or peritoneal mast cells does not influence 
the  antigen-induced  release  of SRS-A  rat.  A  local  increase  in  the  number  of 
PMN leukocytes produced by the induction of a peritoneal exudate was asso- 
ciated with an enhanced release of SRS-A  ~t. 
A  distinct  difference in  the  cellular  requirements  for  the  antigen-induced 
release  of histamine  and SRS-A  ra* in  the  rat was  observed. Homocytotropic 
antibody-mediated histamine release could be achieved in leukopenic rats but 
not in mast cell-depleted animals. Conversely, SRS-A  r~* release was suppressed 
in leukopeuic rats but was unaffected by mast cell depletion. 
Diethylcarbamazine inhibited  the  antigen-induced  release  of SRS-A  *~* fol- 
lowing preparation with homologous, hyperimmune antisera but did not inter- 
fere with homocytotropic antibody-mediated histamine release. In preventing 
SRS-A  ~t release,  diethylcarbamazine did not interfere with antigen-antibody 
interaction since desensitization of tissues was possible in the presence of this 
inhibitor. This observation is consistent with the view that diethylcarbamazine 
inhibits the reaction sequence leading to the formation and release of SRS-A  ~t 
at some step subsequent to antigen-antibody interaction. 
These studies support the view that the immunologic pathways leading to 
the release of SRS-A  ~t and histamine in the rat are distinctly different in terms 
of the immunoglobulins involved, the cellular prerequisites,  and the effective 
pharmacologic inhibitors. 
The authors  gratefully acknowledge the  untiring and  proficient technical assistance of 
Mrs. Ann Kittelberger. 
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